Melanie is an Associate at Forbion and joined the investment team in September 2022 working across both the Ventures and Growth Strategies. Melanie currently serves as a Board member on Gyes and holds an observer role on the Board of Mestag. She has been involved in various investments across both strategies including Capstan (acquired by Abbvie), VOR, and Cellcentric.
Prior to joining Forbion, Melanie obtained her Ph.D degree in Oncology from the University of Vienna. During her graduate studies, she developed new approaches to investigate aberrant transcriptional programs in cancer cells by utilizing genome-wide CRISPR/Cas9 screens. Melanie has published in several high-impact journals including Nature and Science, and received an award from MIT in recognition of her Ph.D work. Prior to her Ph.D, Melanie gained diverse insights into the life science industry, working in Regulatory Affairs at Novo Nordisk and writing for Labiotech.eu.
She holds a MSc. in Human Biology from the University of Copenhagen and a BSc. in Molecular Biotechnology from RWTH Aachen University.
Joining Forbion has been an incredible opportunity to gain unique insights into the biotech ecosystem and leverage the unique expertise of our investment team across diverse therapeutic modalities and areas. With my scientific background, I'm excited to contribute to building innovative biotech companies alongside some of the most experienced professionals in the field.
Portfolio
Companies worked on by Melanie de Almeida
